First assessment of the AcSé program

First assessment of the AcSé program

The National Cancer Institute (INCa), in agreement with the French National Agency for Medicines and Health Products Safety (ANSM), launched an innovative program  in June 2013 for secure access to innovative targeted therapies: the AcSé program. A year and a half later, the INCa and its partners have drawn up a first assessment of this program. 

The AcSé program  offers cancer patients, both adults and children, in whom treatment has failed,  therapies targeting the genetic mutations of their tumors, whatever the organ  affected. AcSé proposes different clinical trials on innovative medicines.

Read the press release

Find out more